RVMD (Revolution Medicines, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RVMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Lorence H. Kim | Director | Sell | — | — |
| 2026-08-25 | Jeff Cislini | General Counsel | MIXED | — | — |
| 2026-08-25 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2026-07-01 | Sushil Patel | Director | MIXED | — | — |
| 2026-06-26 | Jack Anders | Chief Financial Officer | MIXED | — | — |
| 2026-06-23 | Sushil Patel | Director | A | — | — |
| 2026-06-23 | Alexis Borisy | Director | A | — | — |
| 2026-06-23 | Flavia Borellini | Director | A | — | — |
| 2026-06-23 | Sandra Horning | Director | A | — | — |
| 2026-06-23 | Lorence H. Kim | Director | A | — | — |
| 2026-06-23 | ELIZABETH M ANDERSON | Director | A | — | — |
| 2026-06-23 | Frank Clyburn | Director | A | — | — |
| 2023-11-14 | Thilo Schroeder | Director | A | — | — |
| 2023-11-14 | Alexis Borisy | Director | A | — | — |
| 2023-11-14 | Sandra Horning | Director | A | — | — |
| 2023-10-25 | Margaret A Horn | Chief Operating Officer | M | — | — |
| 2023-10-24 | MARK A GOLDSMITH | See Remarks | M | — | — |
| 2023-10-23 | Jack Anders | Chief Financial Officer | M | — | — |
| 2023-10-18 | Margaret A Horn | Chief Operating Officer | MIXED | — | — |
| 2023-10-13 | Stephen Michael Kelsey | See Remarks | Sell | — | — |
| 2023-10-02 | Jeff Cislini | General Counsel | Sell | — | — |
| 2023-09-20 | Jack Anders | Chief Financial Officer | Sell | — | — |
| 2023-09-20 | Jeff Cislini | General Counsel | Sell | — | — |
| 2023-09-20 | MARK A GOLDSMITH | See Remarks | Sell | — | — |
| 2023-09-20 | Stephen Michael Kelsey | See Remarks | Sell | — | — |
| 2023-09-19 | Margaret A Horn | Chief Operating Officer | MIXED | — | — |
| 2023-09-06 | Jack Anders | Chief Financial Officer | MIXED | — | — |
| 2023-09-06 | Barbara Weber | Director | MIXED | — | — |
| 2023-09-06 | MARK A GOLDSMITH | See Remarks | MIXED | — | — |
| 2023-09-01 | Margaret A Horn | Chief Operating Officer | MIXED | — | — |
| 2023-08-17 | Margaret A Horn | Chief Operating Officer | MIXED | — | — |
| 2023-08-03 | Stephen Michael Kelsey | See Remarks | Sell | — | — |
| 2023-08-01 | Jeff Cislini | General Counsel | Sell | — | — |
| 2023-06-22 | Jeff Cislini | General Counsel | Sell | — | — |
| 2023-06-22 | Jack Anders | Chief Financial Officer | Sell | — | — |
| 2023-06-22 | Margaret A Horn | Chief Operating Officer | Sell | — | — |
| 2023-06-22 | Stephen Michael Kelsey | See Remarks | Sell | — | — |
| 2023-06-12 | Lorence H. Kim | Director | A | — | — |
| 2023-06-12 | Sushil Patel | Director | A | — | — |
| 2023-06-12 | ERIC THOMAS SCHMIDT | Director | A | — | — |
| 2023-06-12 | ELIZABETH M ANDERSON | Director | A | — | — |
| 2023-06-12 | Barbara Weber | Director | A | — | — |
| 2023-06-12 | Alexis Borisy | Director | A | — | — |
| 2023-06-12 | Flavia Borellini | Director | A | — | — |
| 2023-03-21 | Xiaolin Wang | See Remarks | Sell | — | — |
| 2023-03-21 | Stephen Michael Kelsey | See Remarks | Sell | — | — |
| 2023-03-21 | Jack Anders | Chief Financial Officer | Sell | — | — |
| 2023-03-21 | Margaret A Horn | See Remarks | Sell | — | — |
| 2023-03-10 | Thilo Schroeder | Director | Buy | — | — |
| 2023-03-03 | MARK A GOLDSMITH | See Remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,933,348 | — |
| — | 10%+ Owner | 7,977,384 | — |
| — | 10%+ Owner | 2,836,037 | — |
| — | Director | 2,340,075 | — |
| — | 10%+ Owner | 1,909,317 | — |
| — | Director | 1,553,134 | — |
| — | 10%+ Owner | 1,419,900 | — |
| — | 10%+ Owner | 798,795 | — |
| — | Director | 705,313 | — |
| — | See Remarks | 409,109 | — |
| — | See Remarks | 273,721 | — |
| — | Chief Financial Officer | 138,716 | — |
| — | 10%+ Owner | 129,258 | — |
| — | 10%+ Owner | 116,334 | — |
| — | General Counsel | 112,801 | — |
| — | Chief Operating Officer | 104,460 | — |
| — | Director | 97,765 | — |
| — | See Remarks | 58,813 | — |
| — | Director | 54,465 | — |
| — | Director | 48,813 | — |
| — | Director | 36,396 | — |
| — | Director | 26,215 | — |
| — | Director | 23,750 | — |
| — | Director | 21,656 | — |
| — | Director | 21,251 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RVMD quote page; the site-wide leaderboard is on the insider transactions hub.